Trial initiation in S Korea rose by 150% from 2006-09

By Nick Taylor

- Last updated on GMT

Related tags: Clinical trials, Clinical trial, South korea

Clinical trials initiated annually in South Korea increased by 150 per cent between 2006 and 2009. Outsourcing-Pharma presents this as part of a visualisation looking at the growth of clinical trials in Asia over the past decade.

India and China dominate discussions about clinical trials in Asia but, according to data from​, it is South Korea that has experienced the fastest growth in recent years. Between 2006 and 2009 the number of trials initiated annually increased from 206 to 513.

South Korea has benefited from the liberalisation of Japanese regulations regarding where clinical trial data is generated. The regulatory shift has driven demand for trials in China, Taiwan, and, as shown in the data, South Korea.

When the data is presented as number of clinical trials initiated per 1m people in the country Singapore is the dominant player in the region. Graphs can be filtered using the dropdown boxes to show data specific to a certain country or year.

Between 2004 and 2005 there is a large leap in the number of clinical trials initiated in all countries. This change is underpinned by a number of factors which are discussed here​.

Below is a heat map showing trials initiated each year per 1m population. Pressing the play button in t bottom left animates the map to show the changes between 2000 and 2009.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us


View more